Introduction
toxins which are amenable to generic modelling with urea, it is rational to assume backdiffusion of such The range of dialysis treatment schedules is rapidly toxic solutes along the nephron similar to that of urea increasing, with renewed interest in daily haemodialysis [3] , and hence reasonable to choose Kr as the renal (HD), continuous ambulatory peritoneal dialysis function reference standard for assessing the dose (CAPD), automated peritoneal dialysis (APD), APD of dialysis. combined with CAPD, and HD combined with It is necessary to go back some 50 years to find the CAPD. A scale has not been developed previously for major studies of renal urea clearance. The dependence uniform measurement and comparison of the dialysis of Kr on urine flow rate (Qu) was modelled by Dole doses provided by this broad range of therapies. The in 1943 [4] as a function of GFR, tubular area, purpose of this communication is to report a model permeability to urea and urine flow rate. These relawhich can be used uniformly to measure and thus tionships were studied in humans by Chassis et al. [5] . explicitly compare the doses of dialysis provided by
The theoretical Dole equation constants were fit to any combination of intermittent and continuous diahuman data of Chassis et al. by Homer Smith [6 ] , lysis treatments. In the development which follows, resulting in these therapies will be analysed with respect to low molecular weight solute clearance using urea as a Kr=0.57(GFR) *exp (1) generic molecule, and the dialysis doses quantitatively
At an average urine flow rate of 1.5 ml/min and a compared with a normal renal clearance reference GFR of 100 ml/min, the normal urea clearance calcustandard.
lated from Equation 1 is 45 ml/min. It is proposed that this value, normalized to body water ( V ) of 35 l, should serve as the normalized renal function reference A renal reference standard standard for assessment of the dose of dialysis relative to normal renal function. The continuous peritoneal In studies of clinical outcome in chronic renal failure, clearance ( Kp) in CAPD is an exact analogue with the level of residual renal function is often considered respect to time of continuous Kr. The CAPD dose to be defined by the glomerular filtration rate (GFR) conventionally is expressed as Kpt/V, where Kpt is [1] . The index of a modern textbook of nephrology either total daily or weekly peritoneal urea clearance usually does not even include the term urea clearance normalized to V. Similar units would seem appropriate ( Kr) which was discarded long ago by renal physiolo-for expressing the normal reference level of renal urea gists as a measure of renal function because of its clearance, ref( Krt/V ). Thus ref( Krt/V ) can be defined strong dependence on urine flow rate due to backdiffu-as 0.045*1440/35=1.85 l of renal urea clearance per sion of urea in the tubules.
litre of body water daily, or 12.96 weekly. Some In sharp contrast, the contribution of residual renal perspective on this reference standard is obtained by function to renal replacement therapy for end-stage comparing it with the currently recommended dose in renal disease ( ESRD) by HD or PD is usually defined CAPD, a daily Kpt/V of 0.29, or 2.0 weekly, which by the renal urea clearance, which is considered to be constitutes~15% of the normal renal ref( Krt/V ) additive to dialyser or peritoneal clearance provided proposed here. In the following model development, in dialysis therapy [2] . In keeping with this view of the dose provided by any combination of intermittent renal function relative to dialysis therapy, it would and continuous therapy will be expressed as standard seem reasonable to define the renal reference standard Kt/V [std( Kt/V )], with daily or weekly units as above, by renal urea clearance. To the extent that uraemic and as a percentage of the normal renal reference standard. In this way, a uniform dose parameter can The time-averaged concentration ( TAC ) with protoxic solutes which have concentration-dependent files 1 and 3 is substantially lower than the steadyuraemic toxicity which can be controlled by dialysis. state concentrations shown equal to the pre-dialysis Toxic solute removal by dialysis and the human kidney concentration in profile 2, typical with CAPD. The are directly proportional to concentration, so we can lower TAC in HD compared with steady-state C in write the following general mass balance expression CAPD confers no known clinical advantage, since V(dC/dt)=G−K*C (2) clinical outcome is not related to blood urea nitrogen (BUN ) [2] , and would seem best interpreted as an where V is solute distribution volume, G is generation inevitable consequence of the high levels of clearance rate and K is clearance. In steady state, such as chronic required for intermittent therapy. In typical thrice renal failure or CAPD when V(dC/dt)=0, Equation 2 weekly HD with Kr=0 as in profile 1, all solute reduces to generated between each HD must be removed in only 0=G−( Kr+Kp)C (3)~5 % of the time interval. Consequently, there is a marked reduction in C during each dialysis, which or greatly reduces the solute removal rate relative to G=( Kr+Kp)C (4) clearance so that the total clearance provided per week is~50% greater than in CAPD with continuous Equation 4 describes urea kinetics only with normal clearance and steady-state concentration (Css) equal renal function, chronic renal failure without dialysis to pre-dialysis Co. In the model development which or in CAPD. The relationship of solute concentration follows, the calculated dose [std( Kt/V )] will represent to clearance in steady state is demonstrated when the continuous clearance required for Css=Co as Equation 4 is rearranged to give shown in Figure 1 , and no advantages will be inferred C=G/( Kr+Kp) (5) to result from the lower TACs resulting with intermittent therapy. Equation 5 demonstrates that C is a precise function of 1/( Kr+Kp), which results in the well-known parabolic relationship of C to Kr with vertical and horizontal asymptotes at low and high levels of Kr. This The standard Kt/V model general curve varies for individual patients only as a function of G.
The kinetic descriptions of intermittent and continuous The constant concentrations characterizing the dialysis which follow contain the assumptions of steady-state relationships between C, K and G with equally spaced dialyses and constant V. Since ultrafilcontinuous clearance no longer hold when intermittent tration contributes negligibly to low molecular weight clearance is provided with classical HD therapy. In solute removal, the assumption of constant V will not this case, a saw-tooth profile results, with peak pre-cause significant error in calculating std( Kt/V ). dialysis (Co) and the trough post-dialysis (Ct) concen-However, the variable volume model [2] would be trations before and after each dialysis separated by required for analysis of delivered intermittent dialysis gradual concentration build up between treatments, as doses in order to estimate the urea distribution volume, shown by the profiles in Figure 1 . Profile 1 represents V, accurately. The assumption of equal spacing simply provides an estimate of the average peak concentration. Although the inputs include single-pool Kt/V (spKt/V ), correction to equilibrated Kt/V (eKt/V ) is made in all instances as a function of the rate of dialysis relative to V [7] . Further, in the case of daily HD and combined therapies, the spKt/V prescribed for each HD may be relatively low, i.e. <1.1, which may result in spuriously low calculated V [2,8] which would require an appropriate volume correction algorithm [8] in clinical use.
Equation 2 can now be written in a general form applicable to both intermittent and continuous therapies in accordance with 
Quantitative comparisons of treatment modalities where spKt/V is the single-pool Kdt/V or KptV (for with the std( Kt/V ) APD); t is duration of intermittent treatment sessions in minutes; N is the frequency of IHD or APD per The effect of different treatment modalities or schedules week; eKt/V is the equilibrated Kt/V calculated from on std( Kt/V ) is analogous to the effect of dialyser spKt/V in accordance with Equation 11 below [8] ; Kp permeability (overall permeability−area product, is any CD between IHD or APD sessions; Kr is KoA) on clearance in a dialyser. Figure 2 depicts the included in spKt/V and in CD intervals; and all units family of curves relating dialyser urea clearance to must be consistent.
blood flow rate ( KdU, Qb) and KoA. Note that KdU is either primarily blood flow rate-or permeabilityeKt/V=spKt/V[1−0.6/(t/60)]+0.03 (11) limited, depending on the level of KoA compared with Qb. When KoA is small relative to Qb, KdU is In the case when CD is zero, profile 1 in Figure 1 with Kp and Kr zero, during the intervals between permeability limited and plateaus with increasing Qb. When KoA is large compared with Qb, the clearance is blood flow limited and increases linearly with Qb. spKt/V for thrice weekly dialysis as well as of the relative risk of mortality (RR) reported elsewhere [10] . An analogous family of curves is depicted in Figure 3 , where std( Kt/V ) is calculated from It can be noted that both std( Kt/V ) and RR plateau in the domain of sp( Kt/V )>1.2, which corresponds Equations 10-12 and 15a and b and plotted as a function of the sp( Kt/V ) delivered during each dialysis to eKt/V of 1.03 when t=3.5 h. These relationships also support the validity of the std( Kt/V ) dosage and the frequency of dialysis (N, number per week) with t held constant at 3.5 h each dialysis. The identity parameter for quantification of intermittent and continuous therapies. line depicted for continuous therapy is analogous to Qb-limited KdU in Figure 1 , with spKt/V an analogue Analysis of the effect of treatment time varying from 1 to 24 h on std( Kt/V ) with daily haemodialysis is of Qb. The frequency of dialysis, N, is analogous to KoA, and the std( Kt/V ) curves reflect the limitation depicted in Figure 5 . The family of curves resulting here is analogous to those in Figure 3 , where t was of dose by time for solute removal relative to that for generation. Note that at each level of N, as the spKt/V constant and N varied. In Figure 5 , N is constant and t is varied from ultra-short (1 h) to continuous dialysis, per treatment increases, the std( Kt/V ) plateaus, reflecting increasingly inefficient solute removal as as with a wearable kidney. The horizontal line A depicts the relationships between std( Kt/V ), spKt/V BUN falls to very low levels during each dialysis as spKt/V increases. The current recommended treatment and t for currently recommended CAPD dosage, while line B displays the relationships required if we were to levels, 2.0 weekly Kpt/V for CAPD and 1.2 spKt/V for thrice weekly dialysis, can be seen to be equivalent double the current CAPD dose using daily HD. Line A shows that to achieve modelled therapy equivalent to in Figure 3 , providing clinical support for the modelled std( Kt/V ) dosage parameter.
weekly CAPD Kpt/V of 2.0, daily spKt/V of 0.8 is required with 1 h dialyses and of 0.3 with 8 h dialyses. In Figure 4 , std( Kt/V ) is plotted as a function of wider range of std( Kt/V ) levels than currently available. For example, therapy protocols using daily HD with appropriate levels of t and spKt/V could easily be developed to provide weekly std( Kt/V ) levels (see Figure 5 ) ranging from 2 up to 5, or 2.5 times the maximal values achieved with thrice weekly therapy. If the modelled time constraints on std( Kt/V ) depicted in Figures 3, 5 and 6 have clinical validity, the plateau on RR as a function of spKt/V with N=3 in Figure 3 should not be seen when RR is examined as a function of std( Kt/V ). The model prediction of several fold increases in dialysis dose with appropriate daily dialysis or a wearable artificial kidney will require appropriate clinical studies to confirm or refute marked improvement in clinical outcome as a function of std( Kt/V ). of clinical outcome and relative mortality over a much
